Open-science model for drug discovery expands to neurodegenerative diseases

Parkinson's disease and Amyotrophic Lateral Sclerosis are the newest frontiers for open science drug discovery, a global movement led by academic scientists that puts knowledge sharing and medication affordability ahead of patents and profits.